Vázquez-Villa Henar, Trabanco Andrés A
Departamento de Química Orgánica , Facultad de Ciencias Químicas , Universidad Complutense de Madrid , E-28040 Madrid , Spain . Email:
Discovery Sciences , Medicinal Chemistry Department , Janssen Research & Development , c/ Jarama 75A , 45007 Toledo , Spain . Email:
Medchemcomm. 2018 Dec 12;10(2):193-199. doi: 10.1039/c8md00524a. eCollection 2019 Feb 1.
Metabotropic glutamate type 7 (mGlu) receptor is a member of the group III family of mGlu receptors. It is widely distributed in the central nervous system (CNS) and is preferentially expressed on presynaptic nerve terminals where it is thought to play a critical role in modulating normal neuronal function and synaptic transmission, making it particularly relevant in neuropharmacology. The lack of small-molecule mGlu7 ligands with adequate potency, selectivity and drug-like properties has resulted in difficulties in the preclinical validation of mGlu7 modulation in disease models. In the last decade, allosteric modulators of mGlu receptors have emerged as valuable tools with good potency, selectivity and physicochemical properties to study and unleash the therapeutic potential of mGlu receptors. This review focusses on the medicinal chemistry of mGlu receptor allosteric ligands discovered since 2008.
代谢型谷氨酸7(mGlu)受体是III组mGlu受体家族的成员。它广泛分布于中枢神经系统(CNS),并优先表达于突触前神经末梢,据认为在调节正常神经元功能和突触传递中起关键作用,这使其在神经药理学中具有特殊意义。缺乏具有足够效力、选择性和类药性质的小分子mGlu7配体,导致在疾病模型中对mGlu7调节进行临床前验证存在困难。在过去十年中,mGlu受体的变构调节剂已成为具有良好效力、选择性和物理化学性质的有价值工具,用于研究和释放mGlu受体的治疗潜力。本综述重点关注自2008年以来发现的mGlu受体变构配体的药物化学。